Guggenheim initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $12 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics Reports Q3 2025 Financial Results
- Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating
- Foghorn Therapeutics CFO Kristian Humer Resigns
- Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)
- Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating